The 2 analysts offering 12-month price forecasts for Caladrius Biosciences Inc have a median target of 9.00, with a high estimate of 10.00 and a low estimate of 8.00. The median estimate represents a +852.89% increase from the last price of 0.94.
The current consensus among 2 polled investment analysts is to Buy stock in Caladrius Biosciences Inc. This rating has held steady since July, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.15
Reporting Date Mar 17
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.